1
|
Ma F, Arai S, Wang K, Calagua C, Yuan AR, Poluben L, Gu Z, Russo JW, Einstein DJ, Ye H, He MX, Liu Y, Van Allen E, Sowalsky AG, Bhasin MK, Yuan X, Balk SP. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer. Cancer Res 2022; 82:1518-1533. [PMID: 35131873 PMCID: PMC9018564 DOI: 10.1158/0008-5472.can-21-1807] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 11/22/2021] [Accepted: 02/02/2022] [Indexed: 11/16/2022]
Abstract
Wnt signaling driven by genomic alterations in genes including APC and CTNNB, which encodes β-catenin, have been implicated in prostate cancer development and progression to metastatic castration-resistant prostate cancer (mCRPC). However, nongenomic drivers and downstream effectors of Wnt signaling in prostate cancer and the therapeutic potential of targeting this pathway in prostate cancer have not been fully established. Here we analyzed Wnt/β-catenin signaling in prostate cancer and identified effectors distinct from those found in other tissues, including aryl hydrocarbon receptor and RUNX1, which are linked to stem cell maintenance, and ROR1, a noncanonical Wnt5a coreceptor. Wnt/β-catenin signaling-mediated increases in ROR1 enhanced noncanonical responses to Wnt5a. Regarding upstream drivers, APC genomic loss, but not its epigenetic downregulation commonly observed in prostate cancer, was strongly associated with Wnt/β-catenin pathway activation in clinical samples. Tumor cell upregulation of the Wnt transporter Wntless (WLS) was strongly associated with Wnt/β-catenin pathway activity in primary prostate cancer but also associated with both canonical and noncanonical Wnt signaling in mCRPC. IHC confirmed tumor cell WLS expression in primary prostate cancer and mCRPC, and patient-derived prostate cancer xenografts expressing WLS were responsive to treatment with Wnt synthesis inhibitor ETC-1922159. These findings reveal that Wnt/β-catenin signaling in prostate cancer drives stem cell maintenance and invasion and primes for noncanonical Wnt signaling through ROR1. They further show that autocrine Wnt production is a nongenomic driver of canonical and noncanonical Wnt signaling in prostate cancer, which can be targeted with Wnt synthesis inhibitors to suppress tumor growth. SIGNIFICANCE This work provides fundamental insights into Wnt signaling and prostate cancer cell biology and indicates that a subset of prostate cancer driven by autocrine Wnt signaling is sensitive to Wnt synthesis inhibitors.
Collapse
Affiliation(s)
- Fen Ma
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
| | - Seiji Arai
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
- Department of Urology, Gunma University Hospital; Maebashi, Gunma, Japan
| | - Keshan Wang
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Wuhan, Hubei 430022, P.R. China
| | - Carla Calagua
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
| | - Amanda R. Yuan
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
| | - Larysa Poluben
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
| | - Zhongkai Gu
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
| | - Joshua W. Russo
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
| | - David J. Einstein
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
| | - Huihui Ye
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
- Department of Pathology, UCLA David Geffen School of Medicine; Los Angeles, CA 90095
| | - Meng Xiao He
- Harvard Graduate Program in Biophysics, Harvard Medical School; Boston, MA 02115, USA
- Department of Medical Oncology, Dana Farber Cancer Institute; Boston, MA 02115
- Broad Institute of Harvard and MIT; Cambridge, MA 02142, USA
| | - Yu Liu
- Program in System Biology, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School; Worcester, MA 01605, USA
| | - Eliezer Van Allen
- Department of Medical Oncology, Dana Farber Cancer Institute; Boston, MA 02115
- Broad Institute of Harvard and MIT; Cambridge, MA 02142, USA
| | - Adam G. Sowalsky
- Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, National Institutes of Health; Bethesda, MD 20892, USA
| | - Manoj K. Bhasin
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
- Departments of Pediatrics and Biomedical Informatics, Emory School of Medicine; Atlanta, GA 30322, USA
| | - Xin Yuan
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
| | - Steven P. Balk
- Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA, 02215, USA
| |
Collapse
|
3
|
Smith EN, Bloss CS, Badner JA, Barrett T, Belmonte PL, Berrettini W, Byerley W, Coryell W, Craig D, Edenberg HJ, Eskin E, Foroud T, Gershon E, Greenwood TA, Hipolito M, Koller DL, Lawson WB, Liu C, Lohoff F, McInnis MG, McMahon FJ, Mirel DB, Nievergelt C, Nurnberger J, Nwulia EA, Paschall J, Potash JB, Rice J, Schulze TG, Scheftner W, Panganiban C, Zaitlen N, Zandi PP, Zöllner S, Schork NJ, Kelsoe JR, Kelsoe JR. Genome-wide association study of bipolar disorder in European American and African American individuals. Mol Psychiatry 2009; 14:755-63. [PMID: 19488044 PMCID: PMC3035981 DOI: 10.1038/mp.2009.43] [Citation(s) in RCA: 283] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
To identify bipolar disorder (BD) genetic susceptibility factors, we conducted two genome-wide association (GWA) studies: one involving a sample of individuals of European ancestry (EA; n=1001 cases; n=1033 controls), and one involving a sample of individuals of African ancestry (AA; n=345 cases; n=670 controls). For the EA sample, single-nucleotide polymorphisms (SNPs) with the strongest statistical evidence for association included rs5907577 in an intergenic region at Xq27.1 (P=1.6 x 10(-6)) and rs10193871 in NAP5 at 2q21.2 (P=9.8 x 10(-6)). For the AA sample, SNPs with the strongest statistical evidence for association included rs2111504 in DPY19L3 at 19q13.11 (P=1.5 x 10(-6)) and rs2769605 in NTRK2 at 9q21.33 (P=4.5 x 10(-5)). We also investigated whether we could provide support for three regions previously associated with BD, and we showed that the ANK3 region replicates in our sample, along with some support for C15Orf53; other evidence implicates BD candidate genes such as SLITRK2. We also tested the hypothesis that BD susceptibility variants exhibit genetic background-dependent effects. SNPs with the strongest statistical evidence for genetic background effects included rs11208285 in ROR1 at 1p31.3 (P=1.4 x 10(-6)), rs4657247 in RGS5 at 1q23.3 (P=4.1 x 10(-6)), and rs7078071 in BTBD16 at 10q26.13 (P=4.5 x 10(-6)). This study is the first to conduct GWA of BD in individuals of AA and suggests that genetic variations that contribute to BD may vary as a function of ancestry.
Collapse
Affiliation(s)
- Erin N. Smith
- Scripps Genomic Medicine and Scripps Translational Science Institute, La Jolla, CA 92037, USA,Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Cinnamon S. Bloss
- Scripps Genomic Medicine and Scripps Translational Science Institute, La Jolla, CA 92037, USA,Scripps Health, La Jolla, CA 92037, USA
| | - Judith A. Badner
- Department of Psychiatry, University of Chicago, Chicago, IL 60637, USA
| | - Thomas Barrett
- Department of Psychiatry, Portland VA Medical Center, Portland, OR, 97239, USA
| | - Pamela L. Belmonte
- Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, 21287, USA
| | - Wade Berrettini
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - William Byerley
- Department of Psychiatry, University of California, San Francisco, CA, 94143, USA
| | - William Coryell
- Department of Psychiatry, University of Iowa, Iowa City, IA 52242, USA
| | - David Craig
- Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
| | - Howard J. Edenberg
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA,Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
| | - Eleazar Eskin
- Department of Computer Science, University of California, Los Angeles, Los Angeles, CA, 90095, USA
| | - Tatiana Foroud
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
| | - Elliot Gershon
- Department of Psychiatry, University of Chicago, Chicago, IL 60637, USA
| | - Tiffany A. Greenwood
- Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093, USA
| | - Maria Hipolito
- Department of Psychiatry, Howard University, Washington, D.C., 20060, USA
| | - Daniel L. Koller
- Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
| | - William B. Lawson
- Department of Psychiatry, Howard University, Washington, D.C., 20060, USA
| | - Chunyu Liu
- Department of Psychiatry, University of Chicago, Chicago, IL 60637, USA
| | - Falk Lohoff
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Melvin G. McInnis
- Department of Psychiatry, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Francis J. McMahon
- Genetic Basis of Mood and Anxiety Disorders Unit, National Institute of Mental Health Intramural Research Program, National Institutes of Health, US Dept of Health and Human Services, Bethesda, MD, 20892, USA
| | - Daniel B. Mirel
- Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, 02142, USA
| | - Caroline Nievergelt
- Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093, USA
| | - John Nurnberger
- Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
| | | | - Justin Paschall
- National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland 20892, USA
| | - James B. Potash
- Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, 21287, USA
| | - John Rice
- Division of Biostatistics, Washington University, St. Louis, MO, 63130, USA
| | - Thomas G. Schulze
- Genetic Basis of Mood and Anxiety Disorders Unit, National Institute of Mental Health Intramural Research Program, National Institutes of Health, US Dept of Health and Human Services, Bethesda, MD, 20892, USA
| | | | - Corrie Panganiban
- Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
| | - Noah Zaitlen
- Department of Computer Science, University of California, Los Angeles, Los Angeles, CA, 90095, USA
| | - Peter P. Zandi
- Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, 21287, USA
| | - Sebastian Zöllner
- Department of Psychiatry, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Nicholas J. Schork
- Scripps Genomic Medicine and Scripps Translational Science Institute, La Jolla, CA 92037, USA,Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - John R. Kelsoe
- Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093, USA,Department of Psychiatry, VA San Diego Healthcare System, La Jolla, CA, 92151, USA
| | | |
Collapse
|